CLASSIFICATION: GROWTH HORMONE RELEASING HORMONE (GHRH)
ACTIVE SUBSTANCE: TESAMORELIN
FORM: 2 ML VIAL x 5 MG (LYOPHILIZED POWDER)
ACTIVE HALF-LIFE: 20 TO 30 MINUTES
DOSAGE: MEN 1 TO 2 MG PER DAY
MANUFACTURER: BRITISH DRAGON
British Dragon Tesamorelin 5 mg is a synthetic analog of growth hormone-releasing hormone (GHRH), specifically the full-length GHRH (1-44) sequence with a chemical modification that enhances its resistance to enzymatic degradation. Each 2 mL vial contains 5 mg of lyophilized Tesamorelin, designed for reconstitution in research settings investigating metabolic function, body composition, and growth hormone regulation.
Tesamorelin acts on the pituitary somatotrophs to stimulate endogenous growth hormone release with greater potency and duration than shorter GHRH analogs. For researchers studying visceral adiposity and metabolic parameters, this peptide offers distinct advantages. Explore similar research compounds like Sermorelin 5 mg or Ipamorelin 5 mg.
Tesamorelin contains a trans-3-hexenoic acid modification at the N-terminus, which confers resistance to dipeptidyl peptidase-4 (DPP-4) degradation, resulting in a longer half-life compared to unmodified GHRH (1-44). This modification allows for once-daily administration in research protocols while maintaining biological activity.
For metabolic research, Tesamorelin has been extensively studied for its effects on visceral adipose tissue and metabolic parameters. The 5 mg dosage provides sufficient material for extended research protocols investigating chronic GHRH analog administration. Researchers may also compare Tesamorelin with Sermorelin to evaluate differences between GHRH fragments and full-length analogs.
British Dragon Tesamorelin 5 mg is intended for laboratory research only. Not for human consumption or clinical use.
External research on Tesamorelin's mechanisms can be explored via PubMed for peer-reviewed studies.
For laboratory research use only. Not for human consumption. Reconstitution and handling must be performed by qualified personnel using sterile techniques.
The standard reconstitution yields a concentration of approximately 1.67-2.5 mg/mL (1670-2500 mcg/mL). For precise dosing, researchers should calculate based on desired mg per injection volume.
In animal models, Tesamorelin is often administered at dosages ranging from 1-2 mg per day. Due to its approximately 2-hour half-life, once-daily administration is typical in prolonged studies. Subcutaneous injection is the standard route for systemic absorption research.
Tesamorelin is often studied in isolation for its effects on GH release and metabolic parameters. However, some protocols combine it with GHRP compounds to evaluate synergistic effects on GH pulsatility. For comprehensive metabolic research, explore our range of MOTS-c 10 mg.
Note: Dosages mentioned are for research purposes only. Individual response varies in animal models. Always follow institutional animal care guidelines when conducting in vivo research.
Third-party analytical testing (COA) for British Dragon Tesamorelin 5 mg is currently not yet available. Batch-specific assay data, purity analysis, and verification documentation will be published once released.
This product is supplied through the official British Dragon distribution chain and shipped in original manufacturer packaging. The outer shipping package remains discreet, with privacy-focused handling and no unnecessary external product details.
For complete delivery details, tracking policy, and reshipment terms, please see our Shipping Info page.
Store British Dragon Tesamorelin 5 mg lyophilized powder in a cool, dry place away from direct light and moisture. Prior to reconstitution, the unopened vial should be kept at controlled room temperature (15-25°C) or refrigerated (2-8°C) for long-term storage. Do not freeze the lyophilized powder, as this may damage the peptide structure.
After reconstitution with bacteriostatic water, the solution must be stored at 2-8°C (refrigerator) and used within 30 days to maintain peptide integrity. Avoid repeated freeze-thaw cycles. Do not use if the solution appears cloudy or contains particulates, or if the vial seal is compromised.
Keep out of reach of children and unauthorized personnel. Follow standard laboratory safety protocols when handling peptides.
Proper storage conditions help maintain research-grade purity and consistent performance across the product's shelf life.
Tesamorelin is studied as a potent GHRH analog that stimulates endogenous growth hormone release. Research applications include metabolic studies, visceral adiposity investigations, and body composition research in animal models.
Add 2-3 mL of bacteriostatic water to the 5 mg vial, swirling gently until fully dissolved. The resulting concentration will be approximately 1.67-2.5 mg/mL depending on the volume used.
In animal studies, dosages often range from 1-2 mg per day, administered once daily due to the approximately 2-hour half-life. Dosing should be scaled appropriately for the research model and study objectives.
Tesamorelin is a full-length GHRH (1-44) analog with a chemical modification that confers DPP-4 resistance and a longer half-life. Sermorelin is a shorter GHRH (1-29) fragment without this modification, resulting in different pharmacokinetic properties.
Third-party COA testing is currently pending. British Dragon is committed to publishing batch-specific lab reports as soon as analytical testing is completed and verified.
Please log in to write TESAMORELIN 5 MG review.
CLASSIFICATION: GROWTH HORMONE RELEASING HORMONE (GHRH)
ACTIVE SUBSTANCE: TESAMORELIN
FORM: 2 ML VIAL x 5 MG (LYOPHILIZED POWDER)
ACTIVE HALF-LIFE: 20 TO 30 MINUTES
DOSAGE: MEN 1 TO 2 MG PER DAY
ACNE: RARE
WATER RETENTION: MINIMAL
HIGH BLOOD PRESSURE (HBP): N/A
HEPATOTOXICITY: NOT OBSERVED
AROMATIZATION: NONE
MANUFACTURER: DRAGON PHARMA
CLASSIFICATION: PEPTIDE HORMONE / HCG
ACTIVE SUBSTANCE: HUMAN CHORIONIC GONADOTROPIN
FORM: 1 ML AMP x 5000 IU
ACTIVE HALF-LIFE: ~3–6 DAYS
DOSAGE: 250–1000 IU 2–3x/WEEK (ON-CYCLE or PCT)
ACNE: POSSIBLE
WATER RETENTION: MODERATE
HIGH BLOOD PRESSURE (HBP): UNLIKELY
HEPATOTOXICITY: NONE
AROMATIZATION: INDIRECTLY ELEVATES ESTROGEN
MANUFACTURER: SUN PHARMA